GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunotech Biopharm Ltd (HKSE:06978) » Definitions » Notes Receivable

Immunotech Biopharm (HKSE:06978) Notes Receivable : HK$0.00 Mil (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Immunotech Biopharm Notes Receivable?

Immunotech Biopharm's Notes Receivable for the quarter that ended in Jun. 2024 was HK$0.00 Mil.


Immunotech Biopharm Notes Receivable Historical Data

The historical data trend for Immunotech Biopharm's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunotech Biopharm Notes Receivable Chart

Immunotech Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial - - - - -

Immunotech Biopharm Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Immunotech Biopharm Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Immunotech Biopharm Notes Receivable Related Terms

Thank you for viewing the detailed overview of Immunotech Biopharm's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunotech Biopharm Business Description

Traded in Other Exchanges
N/A
Address
No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Executives
Jung Hyun Chul
Evodevo Ltd
Tian Jin He Yue Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other
Wu Naifeng 2501 Other
Yan Kaijing 2501 Other
Yan Xijun 2501 Other
Tian Shi Li Kong Gu Ji Tuan You Xian Gong Si 2501 Other
Tian Shi Li Yi Yao Ji Tuan Gu Fen You Xian Gong Si 2501 Other
Tian Jin Di Zhi Tou Zi Guan Li You Xian Gong Si 2501 Other
Tian Jin Fu Hua De Ke Ji Kai Fa You Xian Gong Si 2501 Other
Li Yunhui 2501 Other
Tian Jin Hong Xun Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other
Tian Jin Kang Shun Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other
Tian Jin Shan Zhen Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other
Tian Jin Shun Qi Ke Ji Fa Zhan He Huo Qi Ye You Xian He Huo 2501 Other

Immunotech Biopharm Headlines

No Headlines